86 related articles for article (PubMed ID: 19108583)
1. Immunophilins and HIV-1 V3 loop for structure-based anti-AIDS drug design.
Andrianov AM
J Biomol Struct Dyn; 2009 Feb; 26(4):445-54. PubMed ID: 19108583
[TBL] [Abstract][Full Text] [Related]
2. Computational anti-AIDS drug design based on the analysis of the specific interactions between immunophilins and the HIV-1 gp120 V3 loop. Application to the FK506-binding protein.
Andrianov AM
J Biomol Struct Dyn; 2008 Aug; 26(1):49-56. PubMed ID: 18533725
[TBL] [Abstract][Full Text] [Related]
3. Computational model of the HIV-1 subtype A V3 loop: study on the conformational mobility for structure-based anti-AIDS drug design.
Andrianov AM; Anishchenko IV
J Biomol Struct Dyn; 2009 Oct; 27(2):179-93. PubMed ID: 19583444
[TBL] [Abstract][Full Text] [Related]
4. Conformational preferences of the HIV-1 principal neutralizing determinant.
Andrianov AM
J Biomol Struct Dyn; 2005 Dec; 23(3):267-82. PubMed ID: 16218754
[TBL] [Abstract][Full Text] [Related]
5. Structural analysis of the HIV-1 gp120 V3 loop: application to the HIV-Haiti isolates.
Andrianov AM; Veresov VG
J Biomol Struct Dyn; 2007 Jun; 24(6):597-608. PubMed ID: 17508782
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel anti-HIV-1 agents based on a broadly neutralizing antibody against the envelope gp120 V3 loop: a computational study.
Andrianov AM; Kashyn IA; Tuzikov AV
J Biomol Struct Dyn; 2014 Dec; 32(12):1993-2004. PubMed ID: 24251545
[TBL] [Abstract][Full Text] [Related]
7. Local structural properties of the V3 loop of Thailand HIV-1 isolate.
Andrianov AM
J Biomol Struct Dyn; 2002 Jun; 19(6):973-89. PubMed ID: 12023800
[TBL] [Abstract][Full Text] [Related]
8. Determining the invariant structure elements of the HIV-1 variable V3 loops: insight into the HIV-MN and HIV-Haiti isolates.
Andrianov AM
J Biomol Struct Dyn; 2008 Oct; 26(2):247-54. PubMed ID: 18597546
[TBL] [Abstract][Full Text] [Related]
9. Induced fit in HIV-neutralizing antibody complexes: evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization.
Rosen O; Chill J; Sharon M; Kessler N; Mester B; Zolla-Pazner S; Anglister J
Biochemistry; 2005 May; 44(19):7250-8. PubMed ID: 15882063
[TBL] [Abstract][Full Text] [Related]
10. In silico design of novel broad anti-HIV-1 agents based on glycosphingolipid β-galactosylceramide, a high-affinity receptor for the envelope gp120 V3 loop.
Andrianov AM; Kornoushenko YV; Kashyn IA; Kisel MA; Tuzikov AV
J Biomol Struct Dyn; 2015; 33(5):1051-66. PubMed ID: 24942968
[TBL] [Abstract][Full Text] [Related]
11. [Computer modeling of the promising inhibitors of the HIV-1 subtype A replication as a framework for the rational anti-aids drug design].
Andrianov AM; Anishchenko IV
Biomed Khim; 2011; 57(2):161-73. PubMed ID: 21870601
[TBL] [Abstract][Full Text] [Related]
12. [Conformation of the HIV-1 gp120 V3 loop. Structure functional analysis of the HIV-Haiti viral strain].
Andrianov AM
Tsitologiia; 2006; 48(11):948-57. PubMed ID: 17233480
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design of a constrained peptide mimic of the HIV-1 V3 loop neutralization site.
Ghiara JB; Ferguson DC; Satterthwait AC; Dyson HJ; Wilson IA
J Mol Biol; 1997 Feb; 266(1):31-9. PubMed ID: 9054968
[TBL] [Abstract][Full Text] [Related]
14. Solution structure of the V3 loop of a Thailand HIV isolate.
Gupta G; Anantharamaiah GM; Scott DR; Eldridge JH; Myers G
J Biomol Struct Dyn; 1993 Oct; 11(2):345-66. PubMed ID: 8286061
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel promising targets for anti-AIDS drug developments by computer modeling: application to the HIV-1 gp120 V3 loop.
Andrianov AM; Anishchenko IV; Tuzikov AV
J Chem Inf Model; 2011 Oct; 51(10):2760-7. PubMed ID: 21888425
[TBL] [Abstract][Full Text] [Related]
16. [Study of conformational homology for the HIV-1 gpi20 V3 loop. structural analysis of the HIV-RF and HIV-Thailand viral strains].
Andrianov AM
Biomed Khim; 2006; 52(5):448-57. PubMed ID: 17180919
[TBL] [Abstract][Full Text] [Related]
17. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
[TBL] [Abstract][Full Text] [Related]
18. Conformational preferences of a chimeric peptide HIV-1 immunogen from the C4-V3 domains of gp120 envelope protein of HIV-1 CAN0A based on solution NMR: comparison to a related immunogenic peptide from HIV-1 RF.
Vu HM; de Lorimier R; Moody MA; Haynes BF; Spicer LD
Biochemistry; 1996 Apr; 35(16):5158-65. PubMed ID: 8611499
[TBL] [Abstract][Full Text] [Related]
19. Stabilization of the biologically active conformation of the principal neutralizing determinant of HIV-1(IIIB) containing a cis-proline surrogate: 1H NMR and molecular modeling study.
Garcia J; Dumy P; Rosen O; Anglister J
Biochemistry; 2006 Apr; 45(13):4284-94. PubMed ID: 16566603
[TBL] [Abstract][Full Text] [Related]
20. Structural requirements for and consequences of an antiviral porphyrin binding to the V3 loop of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp120.
Neurath AR; Strick N; Debnath AK
J Mol Recognit; 1995; 8(6):345-57. PubMed ID: 9052975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
